All Comments by Lary Walker

  1. Does IgG therapy prevent Alzheimer's disease?
  2. Gamma-secretase inhibition reduces spine density in vivo via an amyloid precursor protein-dependent pathway.
  3. Traveling Tau—A New Paradigm for Tau- and Other Proteinopathies?
  4. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system.
  5. Driving amyloid toxicity in a yeast model by structural changes: a molecular approach.
  6. Conformational diversity of wild-type Tau fibrils specified by templated conformation change.
  7. Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease.
  8. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial.
  9. Effect of infarcts on dementia in the Baltimore longitudinal study of aging.
  10. Exercise alters the immune profile in Tg2576 Alzheimer mice toward a response coincident with improved cognitive performance and decreased amyloid.
  11. Participation in dementia research: rates and correlates of capacity to give informed consent.
  12. A highly insoluble state of Abeta similar to that of Alzheimer's disease brain is found in Arctic APP transgenic mice.
  13. Alzheimer's disease (AD)-like pathology in aged monkeys after infantile exposure to environmental metal lead (Pb): evidence for a developmental origin and environmental link for AD.
  14. Visualization and classification of amyloid beta supramolecular assemblies.
  15. Persistence of contradicted claims in the literature.